Details for Patent: 8,178,693

Which drugs does patent 8,178,693 protect, and when does it expire?

Patent 8,178,693 protects KOSELUGO and MEKTOVI and is included in two NDAs.

This patent has one hundred and twenty-three patent family members in thirty-four countries.

Summary for Patent: 8,178,693

Title:	N3 alkylated benzimidazole derivatives as MEK inhibitors
Abstract:	Disclosed are compounds of the Formula ##STR00001## and pharmaceutically acceptable salts and prodrugs thereof, wherein A, R.sup.1, R.sup.2, R.sup.7, R.sup.8, and R.sup.9 are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals. Also disclosed is a method of using such compounds in the treatment of hyperproliferative diseases in mammals, and pharmaceutical compositions containing such compounds.
Inventor(s):	Wallace; Eli M. (Boulder, CO), Lyssikatos; Joseph P. (Piedmont, CA), Marlow; Allison L. (Boulder, CO), Hurley; T. Brian (Boulder, CO)
Assignee:	Array Biopharma Inc. (Boulder, CO)
Application Number:	12/824,559
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 8,178,693

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-001	Apr 10, 2020		RX	Yes	No			Y	Y
Astrazeneca	KOSELUGO	selumetinib sulfate	CAPSULE;ORAL	213756-002	Apr 10, 2020		RX	Yes	Yes			Y	Y
Array Biopharma Inc	MEKTOVI	binimetinib	TABLET;ORAL	210498-001	Jun 27, 2018		RX	Yes	Yes			Y	Y

International Family Members for US Patent 8,178,693

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	038971
Argentina	045738
Argentina	090143
Argentina	090144
Austria	449605